Emprise Bank bought a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 2,476 shares of the medical research company's stock, valued at approximately $1,439,000.
Other hedge funds and other institutional investors have also modified their holdings of the company. Sargent Investment Group LLC acquired a new stake in Thermo Fisher Scientific during the 3rd quarter valued at $339,000. Pearl River Capital LLC acquired a new stake in Thermo Fisher Scientific during the 3rd quarter valued at $242,000. Sugarloaf Wealth Management LLC increased its stake in shares of Thermo Fisher Scientific by 21.1% in the 3rd quarter. Sugarloaf Wealth Management LLC now owns 275 shares of the medical research company's stock valued at $139,000 after buying an additional 48 shares during the period. Aigen Investment Management LP acquired a new stake in shares of Thermo Fisher Scientific in the 3rd quarter valued at $1,092,000. Finally, Glenview Trust co increased its stake in shares of Thermo Fisher Scientific by 32.1% in the 3rd quarter. Glenview Trust co now owns 50,905 shares of the medical research company's stock valued at $25,767,000 after buying an additional 12,369 shares during the period. Institutional investors own 89.23% of the company's stock.
Analysts Set New Price Targets
Several equities research analysts have recently commented on TMO shares. HSBC lifted their target price on Thermo Fisher Scientific from $660.00 to $670.00 and gave the company a "buy" rating in a research note on Tuesday, April 30th. Deutsche Bank Aktiengesellschaft lifted their target price on Thermo Fisher Scientific from $600.00 to $610.00 and gave the company a "buy" rating in a research note on Thursday, April 25th. The Goldman Sachs Group lifted their target price on Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a "buy" rating in a research note on Wednesday, April 10th. JPMorgan Chase & Co. lifted their target price on Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an "overweight" rating in a research note on Thursday, April 25th. Finally, Citigroup assumed coverage on Thermo Fisher Scientific in a research report on Monday, March 18th. They issued a "neutral" rating and a $620.00 price target on the stock. Five investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $607.94.
- 16 Top Robotics Companies to Get to Know in 2023
Get Our Latest Research Report on Thermo Fisher Scientific
Thermo Fisher Scientific Trading Up 0.2 %
TMO stock traded up $1.17 during midday trading on Wednesday, hitting $569.17. 1,398,080 shares of the company's stock were exchanged, compared to its average volume of 1,248,825. The stock's fifty day moving average price is $574.45 and its 200-day moving average price is $559.91. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.33 and a current ratio of 1.70. The company has a market cap of $217.26 billion, a PE ratio of 36.51, a price-to-earnings-growth ratio of 2.65 and a beta of 0.79. Thermo Fisher Scientific Inc. has a one year low of $415.60 and a one year high of $603.82.
- Agilent Technologies Stock: Ready to Rise off the Floor
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 EPS for the quarter, beating analysts' consensus estimates of $4.70 by $0.41. The company had revenue of $10.35 billion for the quarter, compared to analyst estimates of $10.14 billion. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. Research analysts predict that Thermo Fisher Scientific Inc. will post 21.65 earnings per share for the current fiscal year.
Thermo Fisher Scientific Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Monday, July 15th. Stockholders of record on Friday, June 14th will be issued a $0.39 dividend. The ex-dividend date is Friday, June 14th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.27%. Thermo Fisher Scientific's dividend payout ratio (DPR) is 10.01%.
Insider Activity
In related news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Tuesday, April 30th. The stock was sold at an average price of $572.41, for a total value of $5,724,100.00. Following the sale, the chief executive officer now owns 123,816 shares of the company's stock, valued at $70,873,516.56. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, SVP Michael A. Boxer sold 2,000 shares of Thermo Fisher Scientific stock in a transaction dated Friday, April 26th. The stock was sold at an average price of $567.94, for a total value of $1,135,880.00. Following the sale, the senior vice president now owns 13,083 shares of the company's stock, valued at $7,430,359.02. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $572.41, for a total value of $5,724,100.00. Following the transaction, the chief executive officer now directly owns 123,816 shares in the company, valued at approximately $70,873,516.56. The disclosure for this sale can be found here. Insiders have sold a total of 22,000 shares of company stock worth $12,532,780 over the last three months. Corporate insiders own 0.34% of the company's stock.
Thermo Fisher Scientific Company Profile
(Free Report)
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Recommended Stories
- Five stocks we like better than Thermo Fisher Scientific
- Stock Dividend Cuts Happen Are You Ready?
- Outlook Therapeutics: Analysts Forecast Over 500% Stock Upside
- The How And Why of Investing in Oil Stocks
- Campbell Soup Co. Targets Fiscal Q4 Stock Recovery
- What is a Secondary Public Offering? What Investors Need to Know
- Zebra Analysts Upgrade Stock, Forecasting Major Reversal
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
→ Collapse of the Petrodollar (From Colonial Metals) (Ad)
Should you invest $1,000 in Thermo Fisher Scientific right now?
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Beginner's Guide to Pot Stock Investing
Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.
Get This Free Report
